Bowel Cancer UK and Beating Bowel Cancer announced as Edinburgh Molecular (EM) Imaging’s Charity partner. 21 March 2018 – EM Imaging, based in Edinburgh, is partnering with Bowel Cancer UK and Beating Bowel Cancer to raise funds for the charity and increase awareness of Scotland’s…
An excerpt for an article written by Morgan Eichensehr, originally published in the Baltimore Business Journal March 16, 2018 – Harpoon Medical Inc.’s $100 million sale to a Southern California medical device company was a deal two years in the making. Bill Niland, the former…
March 5, 2018 – Mironid is delighted to announce the appointment of Dr Steve Felstead as Chief Medical Officer (CMO) Dr Felstead retired from the position of Vice President, Head of Clinical Research, Pharmatherapeutics Division, Pfizer Inc in April 2014. He joined Pfizer in 1989,…
Data supports biologic activity of APL-2 in reducing the growth rate of geographic atrophy CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 22, 2018 – Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today will…
Third sector funder Inspiring Scotland has appointed Sinclair Dunlop of Epidarex Capital as chair of its board of trustees. He succeeds Niall Lothian, who has led the board since Inspiring Scotland was founded in 2008. Today’s announcement coincides with the 10th anniversary of Inspiring Scotland….
Funding for Collaborative Research Center (CRC) 841 at University Medical Center Hamburg-Eppendorf (UKE) extended for 4 years in the amount of nearly EUR 15 million. Topas Therapeutics will act as exclusive partner for indication expansions and translation of research results into clinical development. Hamburg, 25th…
January 15, 2018 – Mironid is delighted to announce the appointment of Dr Enno Klussmann to our Scientific Advisory Board Dr. Klussmann is currently a group leader at the Max Delbrück Center for Molecular Medicine (MDC) Berlin, Germany. Dr Klussmann is internationally renowned for his…
CRESTWOOD, Ky. and CAMBRIDGE, Ma., Dec. 20, 2017- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that, following discussions with the FDA, it has finalized…
RICHMOND, Va., December 19, 2017- Virginia Bio, the premier statewide non-profit association representing the life science industry in the Commonwealth of Virginia, has elected two new members to their Board of Directors for a term of three years. The election took place on December 14,…
LOUISVILLE, Ky. and CAMBRIDGE Mass., Dec. 08, 2017 – Apellis Pharmaceuticals,Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, will present an update on its Phase 1b PHAROAH trial at the 12th Annual Scientific Assembly…